According to a fresh article in Gastroenterology.

Studies of lower doses of danoprevir along with the existing standard of treatment, to reduce overall danoprevir publicity while maintaining the medication's effectiveness, are underway. Interim basic safety and performance data are promising. Hepatitis C is certainly a significant liver disease due to the hepatitis C virus, which is pass on through direct connection with the blood of infected people and eventually affects the liver. Persistent hepatitis C can lead to serious and life-threatening liver problems, including liver harm, cirrhosis, liver failing or liver cancer. Though many people with hepatitis C may not experience symptoms, others might have symptoms such as fatigue, fever, jaundice and stomach pain.Related StoriesThree out of four consumers not really covered for evidence-based obesity treatment servicesSmall subtype of immune cells appears to prevent obesityObesity organizations take aim at says that deny protection of weight problems treatment under affordable treatment actLed by Noyan Gokce, MD, a cardiologist at BMC and a co-employee professor of medication at BUSM, the experts examined adipose tissue samples from both lean and obese individuals. The study subjects, all of whom were receiving care at BMC, included 109 obese people and 17 lean women and men between the age groups of 21 and 55. After obtaining the samples, the tissue was evaluated and biopsied for the amount of inflammation present in the tissue.